We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

115 hedge funds and large institutions have $380M invested in Progenics Pharmaceuticals Inc in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 17

53% more capital invested

Capital invested by funds: $249M → $380M (+$131M)

44% more call options, than puts

Call options by funds: $1.47M | Put options by funds: $1.02M

11% more funds holding

Funds holding: 104 → 115 (+11)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 34

Holders
115
Holders Change
+11
Holders Change %
+10.58%
% of All Funds
3.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
29
Increased
34
Reduced
34
Closed
17
Calls
$1.47M
Puts
$1.02M
Net Calls
+$450K
Net Calls Change
+$2.59M

Top Buyers

Rank Fund Capital Flow
1
PFC
Phocas Financial Corp
California
+$5.71M
2
Goldman Sachs
Goldman Sachs
New York
+$5.38M
3
State Street
State Street
Massachusetts
+$3.36M
4
PWAM
Park West Asset Management
California
+$3.29M
5
HP
HealthInvest Partners
Sweden
+$1.69M

Top Sellers

Rank Fund Capital Flow
1
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$12.4M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$3.6M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$2.08M
4
BBA
Baker Bros. Advisors
New York
-$1.93M
5
RA
Royce & Associates
New York
-$1.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Simplex Trading
101
Simplex Trading
Illinois
$24K +$23.8K +3,942 New
CSS
102
Cubist Systematic Strategies
Connecticut
$12K +$11.7K +1,937 New
Zurich Cantonal Bank
103
Zurich Cantonal Bank
Switzerland
$11K – – –
AG
104
Advisor Group
Arizona
$9K +$8.23K +1,362 New
RFA
105
Reilly Financial Advisors
California
$9K +$8.46K +1,400 New
TRCT
106
Tower Research Capital (TRC)
New York
$8K +$7.41K +1,225 New
MFS
107
MSI Financial Services
Massachusetts
$6K – – –
MA
108
MUFG Americas
New York
$3K -$1.35K -224 -34%
IA
109
IFP Advisors
Florida
$3K – – –
TCIM
110
TIAA CREF Investment Management
New York
$1.83K +$181K +29,984 +12%
PRS
111
Pinkerton Retirement Specialists
Idaho
$1K – – –
GC
112
Globeflex Capital
California
$1K +$671 +111 New
VOYA Investment Management
113
VOYA Investment Management
Georgia
$201 – – –
SM
114
Sabby Management
Florida
– -$738K -174,900 Closed
Invesco
115
Invesco
Georgia
– -$422K -100,059 Closed
TC
116
TFS Capital
Pennsylvania
– -$256K -60,575 Closed
HCM
117
Hollencrest Capital Management
California
– -$211K -50,000 Closed
Ameriprise
118
Ameriprise
Minnesota
– -$156K -37,037 Closed
Axa
119
Axa
France
– -$135K -31,900 Closed
Balyasny Asset Management
120
Balyasny Asset Management
Illinois
– -$103K -24,437 Closed
PAM
121
Princeton Alpha Management
New Jersey
– -$100K -23,774 Closed
SAM
122
Symphony Asset Management
California
– -$63K -14,890 Closed
GCP
123
GSA Capital Partners
United Kingdom
– -$55K -13,100 Closed
VRS
124
Virginia Retirement Systems
Virginia
– -$44K -10,400 Closed
Teacher Retirement System of Texas
125
Teacher Retirement System of Texas
Texas
– -$41K -9,729 Closed
2 3 4
5
6

PGNX Hedge Fund Activity: Q3 2016 in Review

115 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2016, worth a combined $380M — up 53% from $249M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PGNX positions and 17 closed out — a net gain of 12 holders — while 34 added to existing stakes and 34 trimmed.

The largest buyer was Phocas Financial Corp, adding an estimated $5.71M. The largest seller was Tudor Investment Corp, cutting an estimated $12.4M.

  • 115 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2016, up from 104 in Q2 2016.
  • Funds reported $380M of Progenics Pharmaceuticals Inc stock for Q3 2016, up 53% quarter-over-quarter.
  • 29 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2016 and 17 closed out, a net change of +12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2016 was Phocas Financial Corp, an estimated $5.71M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2016 was Tudor Investment Corp, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2016.